NASDAQ:KLRS Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $4.40 -0.32 (-6.78%) Closing price 04:00 PM EasternExtended Trading$4.47 +0.07 (+1.59%) As of 04:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kalaris Therapeutics Stock (NASDAQ:KLRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kalaris Therapeutics alerts:Sign Up Key Stats Today's Range$4.39▼$4.7050-Day Range$4.09▼$6.6052-Week Range$2.14▼$11.88Volume66,298 shsAverage Volume78,300 shsMarket Capitalization$104.68 millionP/E RatioN/ADividend YieldN/APrice Target$15.60Consensus RatingModerate Buy Company Overview Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. Read More Kalaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreKLRS MarketRank™: Kalaris Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 143rd out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingKalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialKalaris Therapeutics has a consensus price target of $15.60, representing about 254.5% upside from its current price of $4.40.Amount of Analyst CoverageKalaris Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Kalaris Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kalaris Therapeutics are expected to grow in the coming year, from ($2.05) to ($1.91) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kalaris Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kalaris Therapeutics is -2.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalaris Therapeutics has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.56% of the float of Kalaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverKalaris Therapeutics has a short interest ratio ("days to cover") of 10.29, which indicates bearish sentiment.Change versus previous monthShort interest in Kalaris Therapeutics has recently decreased by 0.35%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalaris Therapeutics does not currently pay a dividend.Dividend GrowthKalaris Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Kalaris Therapeutics this week, compared to 2 articles on an average week.Search Interest4 people have searched for KLRS on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows4 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $1,179,969.00 in company stock, which represents 1.1273% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Kalaris Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,179,969.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kalaris Therapeutics' insider trading history. Receive KLRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRS Stock News HeadlinesKalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by AnalystsJune 16, 2026 | americanbankingnews.comKalaris Therapeutics (NASDAQ:KLRS) Cut to "Sell" at Wall Street ZenJune 14, 2026 | americanbankingnews.comFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTim Plaehn's income ETF research is available at 82% off - but only until midnight tonight. At just $9, this Independence Day deal gives investors instant access to his dividend-focused ETF strategy. When the clock hits zero, this pricing disappears. For under a dime a day, you can access a structured approach to building income through ETFs.June 22 at 1:00 AM | Investors Alley (Ad)Kalaris to Present at Clinical Trials at the Summit 2026June 12, 2026 | finance.yahoo.comKalaris Therapeutics Stock Price HistoryMay 30, 2026 | investing.comKalaris Therapeutics (NASDAQ:KLRS) Director Srinivas Akkaraju Acquires 244,300 SharesMay 23, 2026 | insidertrades.comKalaris Therapeutics director Akkaraju’s fund buys $1.18m stockMay 22, 2026 | investing.comKalaris Therapeutics Inc KLRSMay 16, 2026 | morningstar.comMSee More Headlines KLRS Stock Analysis - Frequently Asked Questions How have KLRS shares performed this year? Kalaris Therapeutics' stock was trading at $8.44 on January 1st, 2026. Since then, KLRS stock has decreased by 47.9% and is now trading at $4.40. How were Kalaris Therapeutics' earnings last quarter? Kalaris Therapeutics Inc. (NASDAQ:KLRS) released its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.06. Who are Kalaris Therapeutics' major shareholders? Kalaris Therapeutics' top institutional shareholders include Kalehua Capital Management LLC (0.57%), Simplify Asset Management Inc. (0.38%), Renaissance Technologies LLC (0.29%) and WealthTrust Asset Management LLC (0.05%). View institutional ownership trends. How do I buy shares of Kalaris Therapeutics? Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/12/2026Today6/22/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 KLRS's financial health is in the Yellow zone, according to TradeSmith. KLRS has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KLRS CIK1754068 WebN/A Phone(617) 433-2605FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Kalaris Therapeutics$15.60 High Price Target$25.00 Low Price Target$3.00 Potential Upside/Downside+254.5%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-72.78% Return on Assets-43.49% Debt Debt-to-Equity RatioN/A Current Ratio12.19 Quick Ratio12.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book1.05Miscellaneous Outstanding Shares23,790,000Free Float7,590,000Market Cap$104.68 million OptionableN/A Beta0.15 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:KLRS) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredBlackRock's CEO is calling this "the next major evolution"Larry Fink, CEO of BlackRock - the world's largest asset manager with $10 trillion under management - is calli...Awesomely, LLC | SponsoredI’m shouting ‘Buy Now’ before this stock soarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredTrump’s secret China dealTrump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...Porter & Company | SponsoredPrint this before your next tradeBill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97. It'...Profits Run | SponsoredRead this before you touch SPCXSPCX is live on Nasdaq - but a market expert who called AMD before it climbed as high as 7,100% says buying th...Altimetry | SponsoredEvery time Musk needs a company, he buys it. He needs this one.Elon Musk doesn't rent - he buys. When he needed batteries, he built the Gigafactory. When he needed solar, he...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
